Market Place
Sourcing Support
U.S. Consensus Backs MediWound`s Chronic Wound Strategy
13 Apr 2026 //
GLOBENEWSWIRE
MediWound Reports BARDA Grants Vericel $197M for NexoBrid
02 Apr 2026 //
GLOBENEWSWIRE
Mediwound Files Annual Report On Form 20-F
05 Mar 2026 //
GLOBENEWSWIRE
MediWound Reports Q4 and Full Year 2025 Financial Results
05 Mar 2026 //
GLOBENEWSWIRE
MediWound To Release 2025 Q4 & Full-Year Financial Result
19 Feb 2026 //
GLOBENEWSWIRE
Mediwound To Present At Upcoming Investor Conferences
17 Feb 2026 //
GLOBENEWSWIRE
Mediwound Updates Corporate Status Pre-J.P. Morgan Conference
12 Jan 2026 //
GLOBENEWSWIRE
Mediwound Unveils Q3 2025 Financials And Corporate Update
20 Nov 2025 //
GLOBENEWSWIRE
Mediwound To Report Third Quarter 2025 Financial Results
05 Nov 2025 //
GLOBENEWSWIRE
Mediwound Completes Expansion Of GMP Facility For Nexobrid
03 Nov 2025 //
GLOBENEWSWIRE
Mediwound Launches $30M Registered Direct Share Offering
29 Sep 2025 //
GLOBENEWSWIRE
MediWound to Report Second Quarter 2025 Financial Results
04 Aug 2025 //
GLOBENEWSWIRE
MediWound Reports First Quarter 2025 Financial Results
21 May 2025 //
GLOBENEWSWIRE
MediWound Reports Q4 and Full Year 2024 Financial Results
19 Mar 2025 //
GLOBENEWSWIRE
MediWound to ReportQ4 and Full Year 2024 Financial Results
03 Mar 2025 //
GLOBENEWSWIRE
MediWound to launch Phase III trial for venous leg ulcers
13 Feb 2025 //
PRESS RELEASE
MediWound Starts Ph 3 VALUE Trial Of EscharEx In Venous Leg Ulcers
12 Feb 2025 //
GLOBENEWSWIRE
MediWound to Report Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
MediWound to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
MediWound Announces FDA Approval Of NexoBrid® For Pediatric Severe Burns
15 Aug 2024 //
GLOBENEWSWIRE
MediWound Reports Q2 2024 Financial Results And Provides Company Update
14 Aug 2024 //
GLOBENEWSWIRE
MediWound Announces Positive Results From NexoBrid® NEXT Protocol
05 Aug 2024 //
GLOBENEWSWIRE
MediWound to Report Second Quarter 2024 Financial Results
02 Aug 2024 //
GLOBENEWSWIRE
MediWound Publishes EscharEx® Phase II Results For Venous Leg Ulcers
29 Jul 2024 //
GLOBENEWSWIRE
MediWound Secures €16.25M From European Innovation Council
16 Jul 2024 //
GLOBENEWSWIRE
MediWound Announces $25 Million Strategic Private Placement Financing
15 Jul 2024 //
GLOBENEWSWIRE
MediWound Q1 2024 Results And Business Update
29 May 2024 //
GLOBENEWSWIRE
MediWound To Present EscharEx® Phase 2 Data At Wound Care Conferences
25 Apr 2024 //
GLOBENEWSWIRE
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
MediWound Reports Third Quarter 2023 Financial Results
21 Nov 2023 //
GLOBENEWSWIRE
MediWound Reports Second Quarter 2023 Financial Results
15 Aug 2023 //
GLOBENEWSWIRE
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005
10 Jul 2023 //
GLOBENEWSWIRE
MediWound Reports 1Q 2023 FYR and Provides a Company Update
30 May 2023 //
GLOBENEWSWIRE
MediWound Announces an Additional $10 Million Award from BARDA
09 May 2023 //
GLOBENEWSWIRE
MediWound to Present Phase 2 EscharEx® Data at the Symposium
26 Apr 2023 //
GLOBENEWSWIRE
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
16 Mar 2023 //
GLOBENEWSWIRE
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
MediWound Expands its Leadership Team to Help Drive Company’s Future Growth
06 Mar 2023 //
GLOBENEWSWIRE
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
23 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces Closing of $27.5M Registered Offering of Ordinary Shares
07 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares
03 Feb 2023 //
GLOBENEWSWIRE
MediWound Announces FDA Approval of NexoBrid® for Severe Thermal Burns in Adults
30 Dec 2022 //
GLOBENEWSWIRE
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
23 Dec 2022 //
GLOBENEWSWIRE
MediWound Strengthens European Presence of NexoBrid®
20 Dec 2022 //
GLOBENEWSWIRE
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005
19 Dec 2022 //
GLOBENEWSWIRE
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
13 Dec 2022 //
GLOBENEWSWIRE
MediWound Announces a 1-for-7 Reverse Share Split
05 Dec 2022 //
GLOBENEWSWIRE
MediWound Reports Third Quarter 2022 Financial Results
15 Nov 2022 //
GLOBENEWSWIRE
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift
09 Nov 2022 //
GLOBENEWSWIRE
MediWound Announces Formation of Strategic Advisory Board
25 Oct 2022 //
GLOBENEWSWIRE
MediWound`s EscharEx Featured in Oral and Poster Presentations at SAWC
18 Oct 2022 //
GLOBENEWSWIRE
MediWound Announces Closing of Concurrent Registered Direct & Private Offerings
07 Oct 2022 //
GLOBENEWSWIRE
MediWound Announces Concurrent Registered Direct and Private Placement
22 Sep 2022 //
GLOBENEWSWIRE
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid
20 Sep 2022 //
GLOBENEWSWIRE
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th
12 Sep 2022 //
GLOBENEWSWIRE
MediWound Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
MediWound Enhances Its Board and Executive Leadership Team
08 Aug 2022 //
GLOBENEWSWIRE
MediWound Announces U.S. FDA Acceptance of BLA for NexoBrid
03 Aug 2022 //
GLOBENEWSWIRE
